495 related articles for article (PubMed ID: 37392337)
1. Fibrosis-4 Index Score Predicts Concomitant Coronary Artery Diseases Across the Spectrum of Fatty Liver Disease.
McNally BB; Rangan P; Wijarnpreecha K; Fallon MB
Dig Dis Sci; 2023 Sep; 68(9):3765-3773. PubMed ID: 37392337
[TBL] [Abstract][Full Text] [Related]
2. The impact of concomitant hepatitis C virus infection on liver and cardiovascular risks in patients with metabolic-associated fatty liver disease.
Tsai PS; Cheng YM; Wang CC; Kao JH
Eur J Gastroenterol Hepatol; 2023 Nov; 35(11):1278-1283. PubMed ID: 37773778
[TBL] [Abstract][Full Text] [Related]
3. Associations of metabolic dysfunction-associated fatty liver disease and hepatic fibrosis with bone mineral density and risk of osteopenia/osteoporosis in T2DM patients.
Zhang W; Li Y; Li S; Zhou J; Wang K; Li Z; Chen N; Chen X
Front Endocrinol (Lausanne); 2023; 14():1278505. PubMed ID: 38116314
[TBL] [Abstract][Full Text] [Related]
4. Liver Fibrosis Scores and Coronary Artery Disease: Novel Findings in Patients with Metabolic Dysfunction-Associated Fatty Liver Disease.
Lu C; Chen Y; Zhang Y; Zhao X
Diabetes Metab Syndr Obes; 2023; 16():2627-2637. PubMed ID: 37663203
[TBL] [Abstract][Full Text] [Related]
5. Fibrosis score 4 index has an independent relationship with coronary artery diseases in patients with metabolic-associated fatty liver disease.
Namakchian M; Rabizadeh S; Seifouri S; Asadigandomani H; Bafrani MA; Seifouri K; Avanaki FA; Rajab A; Nakhjavani M; Esteghamati A
Diabetol Metab Syndr; 2023 Mar; 15(1):57. PubMed ID: 36964605
[TBL] [Abstract][Full Text] [Related]
6. MAFLD Predicts the Risk of Cardiovascular Disease Better than NAFLD in Asymptomatic Subjects with Health Check-Ups.
Kim H; Lee CJ; Ahn SH; Lee KS; Lee BK; Baik SJ; Kim SU; Lee JI
Dig Dis Sci; 2022 Oct; 67(10):4919-4928. PubMed ID: 35579799
[TBL] [Abstract][Full Text] [Related]
7. Genetic predisposition in metabolic-dysfunction-associated fatty liver disease and cardiovascular outcomes-Systematic review.
Ismaiel A; Dumitrascu DL
Eur J Clin Invest; 2020 Oct; 50(10):e13331. PubMed ID: 32589269
[TBL] [Abstract][Full Text] [Related]
8. MAFLD identifies patients with significant hepatic fibrosis better than NAFLD.
Yamamura S; Eslam M; Kawaguchi T; Tsutsumi T; Nakano D; Yoshinaga S; Takahashi H; Anzai K; George J; Torimura T
Liver Int; 2020 Dec; 40(12):3018-3030. PubMed ID: 32997882
[TBL] [Abstract][Full Text] [Related]
9. Noninvasive fibrosis tools in NAFLD: validation of APRI, BARD, FIB-4, NAFLD fibrosis score, and Hepamet fibrosis score in a Portuguese population.
Rigor J; Diegues A; Presa J; Barata P; Martins-Mendes D
Postgrad Med; 2022 May; 134(4):435-440. PubMed ID: 35332833
[TBL] [Abstract][Full Text] [Related]
10. Fibrotic Burden Determines Cardiovascular Risk among Subjects with Metabolic Dysfunction-Associated Fatty Liver Disease.
Han E; Lee YH; Lee JS; Lee HW; Kim BK; Park JY; Kim DY; Ahn SH; Lee BW; Kang ES; Cha BS; Kim SU
Gut Liver; 2022 Sep; 16(5):786-797. PubMed ID: 35321955
[TBL] [Abstract][Full Text] [Related]
11. Non-invasive Screening of Metabolic Associated Fatty Liver Disease and Affecting Factors in Primary Care.
Balci IC; Haciagaoglu N; Oner C; Cetin H; Simsek EE
J Coll Physicians Surg Pak; 2023 Apr; 33(4):390-395. PubMed ID: 37190709
[TBL] [Abstract][Full Text] [Related]
12. MAFLD might be better in identifying subjects with sarcopenia or cardiovascular risk than NAFLD: A nationwide study.
Han E; Chun HS; Lee YH; Lee JS; Lee HW; Kim BK; Park JY; Kim DY; Lee BW; Kang ES; Cha BS; Ahn SH; Kim SU
J Gastroenterol Hepatol; 2023 Sep; 38(9):1598-1609. PubMed ID: 37321651
[TBL] [Abstract][Full Text] [Related]
13. Metabolic associated fatty liver disease better identifying patients at risk of liver and cardiovascular complications.
Cheng YM; Wang CC; Kao JH
Hepatol Int; 2023 Apr; 17(2):350-356. PubMed ID: 36471232
[TBL] [Abstract][Full Text] [Related]
14. Metabolic dysfunction associated fatty liver disease identifies subjects with cardiovascular risk better than non-alcoholic fatty liver disease.
Chun HS; Lee M; Lee JS; Lee HW; Kim BK; Park JY; Kim DY; Ahn SH; Lee YH; Kim JH; Kim SU
Liver Int; 2023 Mar; 43(3):608-625. PubMed ID: 36585250
[TBL] [Abstract][Full Text] [Related]
15. Non-invasive screening, staging and management of metabolic dysfunction-associated fatty liver disease (MAFLD) in type 2 diabetes mellitus patients: what do we know so far ?
Binet Q; Loumaye A; Preumont V; Thissen JP; Hermans MP; Lanthier N
Acta Gastroenterol Belg; 2022; 85(2):346-357. PubMed ID: 35709779
[TBL] [Abstract][Full Text] [Related]
16. Risk stratification using sarcopenia status among subjects with metabolic dysfunction-associated fatty liver disease.
Chun HS; Kim MN; Lee JS; Lee HW; Kim BK; Park JY; Kim DY; Ahn SH; Kim SU
J Cachexia Sarcopenia Muscle; 2021 Oct; 12(5):1168-1178. PubMed ID: 34337887
[TBL] [Abstract][Full Text] [Related]
17. Clinical and Histologic Features of Patients with Biopsy-Proven Metabolic Dysfunction-Associated Fatty Liver Disease.
Huang SC; Su HJ; Kao JH; Tseng TC; Yang HC; Su TH; Chen PJ; Liu CJ
Gut Liver; 2021 May; 15(3):451-458. PubMed ID: 33431715
[TBL] [Abstract][Full Text] [Related]
18. Metabolic dysfunction is associated with steatosis but no other histologic features in nonalcoholic fatty liver disease.
Dai YN; Xu CF; Pan HY; Huang HJ; Chen MJ; Li YM; Yu CH
World J Clin Cases; 2022 May; 10(13):4097-4109. PubMed ID: 35665109
[TBL] [Abstract][Full Text] [Related]
19. Ultrasonographic findings of metabolic dysfunction-associated fatty liver disease: A comparative study with non-alcoholic fatty liver disease and clinical characteristics.
Song BG; Kang TW; Sinn DH; Kim YY; Min JH; Hwang JA; Shin J
Clin Imaging; 2024 Apr; 108():110097. PubMed ID: 38310832
[TBL] [Abstract][Full Text] [Related]
20. Comparison of all-cause mortality associated with non-alcoholic fatty liver disease and metabolic dysfunction-associated fatty liver disease in Taiwan MJ cohort.
Cheng WC; Chen HF; Cheng HC; Li CY
Epidemiol Health; 2024; 46():e2024024. PubMed ID: 38317531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]